Browsing Tag
AML
6 posts
ATNM-400 from Actinium Pharmaceuticals (ATNM) shows breakthrough promise in resistant breast cancer
Actinium’s ATNM-400 shows potent activity in resistant breast cancer and TNBC. Find out what the new SABCS 2025 data reveal about this radiopharma candidate.
How SymphonyAI’s Sensa Risk Intelligence aims to transform financial compliance with AI-driven automation
Discover how SymphonyAI’s Sensa Risk Intelligence is transforming financial compliance with enterprise-ready AI. Read what it means for banks today.
How Syndax’s Revuforj (revumenib) became the first FDA-approved menin inhibitor for acute leukemia patients
Find out how Syndax’s Revuforj (revumenib) became the first FDA-approved menin inhibitor for acute leukemia, transforming treatment and investor sentiment alike.
OncoVerity accelerates AML treatment with Series A extension
OncoVerity, a leader in integrating bioinformatics with oncology drug development, has closed a Series A extension financing round,…
Why Kura Oncology shares tumbled after securing a $1.2bn cancer-drug partnership
Kura Oncology, Inc., a clinical-stage biopharmaceutical innovator, and Japan-based pharmaceutical leader Kyowa Kirin Co., Ltd., have entered into…
Chimeric Therapeutics announces breakthrough AML response with CHM CORE-NK in Phase 1B trial
Chimeric Therapeutics has reported a significant milestone in its ongoing clinical trials, wherein a patient diagnosed with Acute…